Fidelis Capital Partners LLC Acquires 114 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fidelis Capital Partners LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 534 shares of the biopharmaceutical company’s stock after buying an additional 114 shares during the period. Fidelis Capital Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $570,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Sachetta LLC increased its position in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Stephens Consulting LLC bought a new position in Regeneron Pharmaceuticals in the second quarter worth about $26,000. West Paces Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 23 shares during the period. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $28,000. Finally, Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $1,145.03 on Monday. The firm’s 50-day moving average price is $1,131.75 and its 200-day moving average price is $1,032.63. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The company has a market cap of $126.17 billion, a PE ratio of 33.83, a PEG ratio of 3.93 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the company posted $8.79 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on REGN shares. Guggenheim raised their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Royal Bank of Canada reissued an “outperform” rating and set a $1,282.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 17th. Piper Sandler upped their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Finally, StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,111.30.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares of the company’s stock, valued at approximately $13,540,179.41. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders sold 9,270 shares of company stock valued at $10,695,833 over the last 90 days. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.